ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New Yor...
September 05 2017 - 06:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today it will be featured
as a presenting company at the 19th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC. The conference is being held on September
10-12, 2017 at Lotte New York Palace Hotel in New York City.
James Sapirstein, Chief Executive Officer, of ContraVir will
provide an overview of the Company's business during the live
presentation and will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
Event: 19th Annual Rodman & Renshaw
Global Investment Conference
Date: September 11, 2017
Time: 10:50 – 11:15AM (Eastern Time)
Location: Kennedy II, Lotte New York
Palace Hotel in New York City
The presentation will be webcast live. To access the
webcast, please visit www.rodmanevents.com. The webcast
replay will remain available for 90 days following the live
presentation.
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2a, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target side-effects
caused by high levels of circulating TFV. CRV431, the other
anti-HBV compound, is a next-generation cyclophilin inhibitor with
a unique structure that increases its potency and selective index
against HBV. ContraVir is also developing Valnivudine™, an orally
available nucleoside analogue prodrug; Valnivudine™ is currently in
Phase 3 for the treatment of herpes zoster. In addition to
direct antiviral activity, Phase 2 data suggest that Valnivudine™
has the potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia
(PHN). For more information visit www.contravir.com.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking
statements are based on ContraVir's current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; our ability to continue as
a going concern; our need for additional financing; uncertainties
of patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-K for the year ended June 30, 2016 and other
periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Mar 2023 to Mar 2024